Intestinal CCL25 expression is increased in colitis and correlates with inflammatory activity
Trivedi, Palak J; Bruns, Tony; Ward, Stephen; Mai, Martina; Schmidt, Carsten; Hirschfield, Gideon M; Weston, Chris J; Adams, David H

DOI: 10.1016/j.jaut.2016.01.001
License: Creative Commons: Attribution (CC BY)

Document Version
Publisher's PDF, also known as Version of record

Citation for published version (Harvard):
Trivedi, PJ, Bruns, T, Ward, S, Mai, M, Schmidt, C, Hirschfield, GM, Weston, CJ & Adams, DH 2016, 'Intestinal CCL25 expression is increased in colitis and correlates with inflammatory activity', Journal of Autoimmunity, vol. 68, pp. 98–104. https://doi.org/10.1016/j.jaut.2016.01.001

Link to publication on Research at Birmingham portal

Publisher Rights Statement:
Checked for eligibility: 01/03/2016

General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

• Users may freely distribute the URL that is used to identify this publication.
• Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
• User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
• Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Download date: 11. Mar. 2020
Short communication

Intestinal CCL25 expression is increased in colitis and correlates with inflammatory activity

Palak J. Trivedi a, b, Tony Bruns a, c, d, Stephen Ward a, c, Martina Mai c, d, Carsten Schmidt c, Gideon M. Hirschfield a, b, Chris J. Weston a, David H. Adams a, b, * 

a National Institute for Health Research (NIHR) Birmingham Liver Biomedical Research Unit (BRU), Institute of Immunology and Immunotherapy, University of Birmingham, United Kingdom 
b Liver Unit, Queen Elizabeth Hospital, Birmingham, United Kingdom 
c Dept. of Internal Medicine IV, University Hospital Jena, Jena, Germany 
d Center for Sepsis Control and Care, University Hospital Jena, Jena, Germany 

CCL25-mediated activation of CCR9 is critical for mucosal lymphocyte recruitment to the intestine. In immune-mediated liver injury complicating inflammatory bowel disease, intrahepatic activation of this pathway allows mucosal lymphocytes to be recruited to the liver, driving hepatobiliary destruction in primary sclerosing cholangitis (PSC). However, in mice and healthy humans CCL25 expression is restricted to the small bowel, whereas few data exist on activation of this pathway in the inflamed colon despite the vast majority of PSC patients having ulcerative colitis. Herein, we show that colonic CCL25 expression is not only upregulated in patients with active colitis, but strongly correlates with endoscopic Mayo score and mucosal TNFα expression. Moreover, approximately 90% (CD4+ and 30% (CD8+) of tissue-infiltrating T-cells in colitis were identified as CCR9+ effector lymphocytes, compared to <10% of T-cells being CCR9+ in normal colon. Sorted CCR9+ lymphocytes also demonstrated enhanced cellular adhesion to stimulated hepatic sinusoidal endothelium compared with their CCR9− counterparts when under flow. Collectively, these results suggest that CCR9/CCL25 interactions are not only involved in colitis pathogenesis but also correlate with colonic inflammatory burden; further supporting the existence of overlapping mucosal lymphocyte recruitment pathways between the inflamed colon and liver.

© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

1. Introduction

Immune cell entry into tissues is a highly coordinated process controlled by the selective expression of cell adhesion receptors on circulating leucocyte subsets and their respective ligands within distinct vascular beds. In the gut, different intestinal sites show distinct patterns of constitutive chemokine expression, which compartmentalises different types of immune cells to particular regions. For example, under non-inflammatory conditions the chemokine CCL25 is expressed by small intestinal but not colonic epithelium, where it supports the recruitment of T-cells and B-cells expressing its receptor CCR9 [1]; whereas CCR10 and G Protein-Coupled Receptor (GPR)-15 are involved in recruiting IgA+ plasmablasts and T-cells, respectively, to the colon [2–4]. These findings suggest that expression levels of chemokines may shape regional differences in immune composition along the intestine. However most of these studies have been done in mice [5,6], and there is a relative paucity of information about the roles of CCL25 and CCR9 in the human colon under inflammatory conditions. This is important as the CCR9/CCL25 pathway is being targeted to treat inflammatory bowel disease (IBD) and evidence of upregulation in active colitis would support clinical studies of anti-CCR9 therapy [7]. To this effect, a recently published randomised controlled trial in Crohn’s disease demonstrated therapeutic benefit of oral CCR9-antagonist over placebo only in the subset of patients with colonic involvement [8].

The intestinal and hepatic immune systems are intimately linked and venous drainage from the gut flows through the liver. The liver acts as a “firewall” and second site of immune regulation

Please cite this article in press as: P.J. Trivedi, et al., Intestinal CCL25 expression is increased in colitis and correlates with inflammatory activity, Journal of Autoimmunity (2016), http://dx.doi.org/10.1016/j.jaut.2016.01.001
to deal with pathogens or antigens that escape immune control in the gut [9]. This close relationship probably explains why the liver is affected as an extra-intestinal site of injury in inflammatory bowel disease (IBD) [10]; exemplified by the fact that >80% of patients with the immune-mediated liver disease, primary sclerosing cholangitis (PSC), develop colitis [11]. One hypothesis to explain the clinical association between PSC and IBD suggests that mucosal effector T-cells are recruited to the liver in response to aberrant hepatic endothelial expression of adhesion molecules, which ordinarily are restricted to the gut [12,13]. Although CCL25 is normally confined to the small intestine, we have reported strong expression on hepatic vessels in the inflamed liver, together with that of another gut-associated adhesion molecule, mucosal addressin cell-adhesion molecule (MAdCAM)-1 [12,13], which collectively drive recruitment of mucosal α4β7⁺CCR9⁺ effector T-cells from gut to liver in PSC [12,13]. However, the IBD associated CD8⁺ cholangitis (PSC), develop colitis [11]. One hypothesis to explain the patients with the immune-mediated liver disease, primary sclerosing cholangitis (PSC), develop colitis [11]. One hypothesis to explain the patients with the immune-mediated liver disease, primary sclerosing cholangitis (PSC), develop colitis [11]. One hypothesis to explain the patients with the immune-mediated liver disease, primary sclerosing cholangitis (PSC), develop colitis [11]. One hypothesis to explain the patients with the immune-mediated liver disease, primary sclerosing cholangitis (PSC), develop colitis [11]. One hypothesis to explain the patients with the immune-mediated liver disease, primary sclerosing cholangitis (PSC), develop colitis [11]. One hypothesis to explain the patients with the immune-mediated liver disease, primary sclerosing cholangitis (PSC), develop colitis [11]. One hypothesis to explain the patients with the immune-mediated liver disease, primary sclerosing cholangitis (PSC), develop colitis [11].

2. Materials and methods

2.1. Intestinal tissue sampling

Intestinal tissue was obtained from patients undergoing surgery for refractory UC or stricturing colon Crohn’s disease. Control specimens were retrieved from ‘distal-to-tumour’ segments of non-IBD associated colorectal cancer (NC) — an absence of colonic inflammation being confirmed histologically. Colonic mucosal biopsies were obtained from patients with UC undergoing colono-scopic surveillance as part of routine standard of care. Human liver tissue was obtained through the Liver Unit at the Queen Elizabeth Hospital, from explanted livers removed at transplantation. Ethical approval was obtained from the local research and ethics committee and all patients granted full prior consent.

2.2. Preparation of tissue-infiltrating lymphocytes for flow cytometry

Mechanical digestion of tissue was carried out using the GentleMACS dissociator (Miltenyi Biotec Ltd, Surrey, UK) and mononuclear cell extraction performed via gradient centrifugation, as previously described [20]. The respective antibodies used to phenotype subsets and appropriate isotype-matched controls are provided in Supplementary Table 1. Samples were analysed in PBS/1 mM EDTA/2% PBS using a CyAn ADP 3-laser, 9-colour flow cytometer (Beckman Coulter Inc, Brea, CA, USA). CCR9 positive populations were defined by gating on live, CD3⁺, and either CD4⁺ or CD8⁺ cells. Dead cells were excluded using Near-IR live/dead-fixable dye (Life Technologies Ltd, Paisley, UK).

2.3. Fluorescence-activated cell (FAC)-sorting and flow-based adhesion assays

To obtain purified populations of T-cells for functional assays, antibody-labelled cells were sorted using a MoFlo XDP High-Speed Cell Sorter (Beckman Coulter Inc., Brea, California, USA) in purity mode.

Flow-based adhesion assays were conducted to compare the ability of sorted α4β7⁺CCR9⁺ versus α4β7⁺CCR9⁺ T-cells to adhere and transmigrate across stimulated human hepatic sinusoidal endothelial cells (HSEC) [21–23]. Briefly, HSEC were extracted from 150 g explanted liver tissue as previously described [21–23] and grown till confluence. At passage 3–4, HSEC were transferred to micro-capillaries for further culture, and when a confluent monolayer was evident they were stimulated with TNFα and methylamine as described by Liaskou et al. [22], prior to perfusion of purified T-cell populations at a shear stress of 0.05 Pa. T-cells that had adhered to HSEC were visualized by phase contrast microscopy (10 × objective) and classified as static (firmly adherent) or migrated cells. Total adhesion was calculated as cells/mm² normalised to the number of lymphocytes perfused [23].

2.3.1. Protein immunoprecipitation and western blotting

Protein was extracted from 60 to 100 mg snap-frozen tissue by incubation in ice-cold lysis buffer (Celllytic MT – Sigma–Aldrich Ltd, Dorset, UK) containing protease inhibitor (Complete Mini – Roche, Indianapolis, USA), phosphatase inhibitor (PhosSTOP – Roche) and DNase I (Roche). Lysate protein concentrations were determined using a bicinchoninic acid (BCA) assay and normalised to 2 mg ml⁻¹. Given that chemokines are often found at low levels in tissues with a propensity to self-aggregate and multimerise [24], an immunoprecipitation step (IP) was incorporated to enrich and purify protein lysates. In brief, 0.6 mg of protein G Dynabeads® (Life Technologies Ltd., Paisley, UK) were incubated with capture antibody (goat polyclonal anti-human CCL25; Cat No.: AF334 – R&D systems, Minneapolis, USA) at ambient temperature under continuous rotation (1 h) and the sample lysate added (continuous rotation; 1 h). Magnetic separation was used to obtain bead bound protein, and non-bound cleared lysate kept for analysis of housekeeping protein and as a negative internal control for the primary target. The remaining bead-bound sample was washed and subjected to temperature dissociation (70 °C, 20 min) to remove beads prior to resuspension in SDS-PAGE sample buffer (200 mM Trizma Base pH 6.8, 20% glycerol, 10% SDS, 0.05% bromophenol blue, 10 mM β-mercaptoethanol).

Immunoprecipitated protein or cleared lysate (20 μg) from each sample was resolved on a 12% SDS–PAGE gel and transferred to a nitrocellulose membrane. Membranes were blocked in 5% non-fat milk dissolved in PBS-Tween20 at ambient temperature (1 h) and subsequently incubated overnight at 4 °C with primary detection antibody (mouse raised against human CCL25: Clone 52529 – R&D systems; or clone 12.4G1–1G4–1C9 – Peprotech, New Jersey, USA) or housekeeping protein (mouse raised against human β-actin: clone AC-74 – Sigma) diluted in 5% milk/PBS-Tween20. The following day, membranes were incubated with horseradish peroxidase conjugated anti-mouse secondary antibodies (1 h; ambient temperature) (Dako Ltd., Cambridge, UK; 1:2500 dilution). Protein bands were detected with the PicoWest ECL system (Thermo Fisher Scientific Inc., Rockford, USA). Membranes were not stripped.

2.3.2. Enzyme-linked immunosorbent assay (ELISA)

ELISA for detection of CCL25 was performed on protein lysates from resected tissue according to manufacturers instructions (2BScientific Ltd., Upper Heyford, UK).

2.4. Gene-expression studies

RNA was extracted from snap-frozen tissue samples using the Qiagen RNeasy mini-kit with or without DNase digestion (Qiagen GmbH, Hilden, Germany). Quantification and purity of RNA was determined by UV absorbance at 260 nm and 280 nm (Implen
Nanophotometer, Geneflow Ltd., Lichfield, UK) and concentration adjusted to 50 μg ml⁻¹. One microgram of RNA was reverse-transcribed using the iScript cDNA synthesis kit (Bio-Rad Inc, Hercules, USA). Differences in target mRNA expression between UC and NC was determined in triplicate for each sample by quantitative real-time PCR (qRT-PCR) (Roche Lightcycler 480; TaqMan Assay Mix, Life Technologies). All primers and probes spanned exon–exon junctions and were pre-designed and obtained from Life Technologies (Supplementary Table 2). For relative quantification analysis, data were normalised to the appropriate housekeeping gene using GeNorm and Bestkeeper algorithms in normal colon as well as colonic cancer [20]. Indeed, GUS-β as being highly conserved by GeNorm and Bestkeeper algorithms in normal colon as well as colonic cancer [20]. We have recently determined GUS-β as being highly conserved by GeNorm and Bestkeeper algorithms in normal colon as well as colonic cancer [20]. Indeed, GUS-β illustrated stable expression between UC and NC specimens, as well as across ordinal degrees of colonic inflammatory activity (data not shown), and was therefore considered a suitable housekeeping gene for assessment in this context.

2.5. Statistical analysis

The distribution of continuous variables was tested using the Kolmogorov–Smirnov test. Non-parametric data are presented as median and interquartile range (IQR); or mean and standard deviation (SD) if confirming to a normal distribution. The Mann–Whitney (MW) test and the Kruskal-Wallis test were conducted when comparing between two or more independent groups, respectively. Non-parametric measures of statistical dependence between two continuous variables were conducted using Spearman’s rank correlation coefficient.

3. Results

3.1. CCR9⁺ T-cells are present in inflamed but not normal human colon

Consistent with prior reports, we found that 62.4% (SD ±19.7%) of tissue-infiltrating CD4⁺ and 68.2% (±12.4%) of CD8⁺ T-cells were CCR9⁺ in the terminal ileum/small bowel (Fig. 1A) whereas very few CCR9⁺ T-cells were detected in normal colon (5.5 ± 0.5% and 4.9 ± 2.4%, respectively). In contrast, specimens from patients with ulcerative colitis refractory to medical therapy contained significantly more CCR9 expressing CD4⁺ (92.6 ± 4.1%; p < 0.001) and CD8⁺ T-cells (34.3 ± 3.8%; p = 0.013) than non-inflamed colon. Increased frequencies albeit at lower levels were also seen in large bowel specimens with only microscopic colitis. The majority of CD4⁺ CCR9⁺ T-cells were CD127⁺, with little or no expression of CD25. Collectively, these findings suggest that effector CCR9⁺ lymphocytes, but not regulatory T-cells (Treg), infiltrate the inflamed colon (Fig. 1B).

Phenotypically, UC is characterised by continuous involvement of the colon starting at the rectum and showing variable proximal extension [25]. Crohn’s disease on the other hand is typified by the presence of skip lesions in which regions of active disease are interspersed with segments free of inflammatory involvement [26]. To test the hypothesis that colonic CCR9⁺ lymphocytes are restricted to areas of active inflammation, we compared tissue-infiltrating T-cell populations in resected Crohn’s inflammatory strictures with those in neighbouring segments of uninvolved colon (Fig. 1C). In the cases studied, >80% of CD4⁺ and >40% of CD8⁺ T-cells in regions of active inflammatory stricture were CCR9⁺ positive compared with ~30% and ~7% in non-inflamed colon from the same patients.

3.2. α4β7⁺CCR9⁺ T-cells undergo adhesion and transmigration across HSEC

We have previously shown that HSEC can support the recruitment of gut-tropic α4β7⁺ lymphocytes, following endothelial stimulation with TNFα and methylamine [22]. Extending these observations further, a significantly greater proportion of FAC-sorted α4β7⁺CCR9⁺ T-cells underwent adhesion to stimulated HSEC under flow, relative to that observed for α4β7⁺CCR9⁺ T-cells (Supplementary Fig. 1).

3.3. Colonic CCL25 expression is upregulated in colitis

Having demonstrated a population of tissue-infiltrating CCR9⁺ T-cells in the inflamed colon, we proceeded to look for its cognate ligand. Indeed, CCL25 mRNA expression was detected in resected colonic tissue from patients with refractory colitis (n = 10; median expression relative to GUS-β: 9.6e⁻⁴; IQR 2.0e⁻⁴ – 3.2e⁻³) but not in normal colonic tissue (n = 10). These differences were reflected in increased CCL25 protein expression measured by immunoprecipitation and western blotting (Fig. 2A), and confirmed using ELISA analysis of the same tissue protein lysates (Fig. 2B).

3.4. CCL25 expression in the colon correlates with severity of colitis

To determine whether CCL25 expression is detectable in colitis during earlier stages of inflammation, mucosal biopsies were obtained from individuals with ulcerative colitis undergoing colonoscopy as part of routine standard of care (kindly provided by University Hospital Jena (Germany); Table 1). Although mucosal biopsies are not large enough for protein or single cell flow-cytometry analysis, we were able to quantify CCL25 mRNA expression and demonstrate a significant correlation with both mucosal inflammation as assessed by the endoscopic Mayo score, and colonic TNFα transcription as an alternative marker of inflammatory activity (Fig. 2C and D).

No significant differences in CCL25 expression were revealed between colonic biopsy site, treatment status with aminosalicylates, immunosuppressive exposure (stratified according to use of steroids, thiopurines, calcineurin inhibitors, biological therapy) or patient age (data not shown).

4. Discussion

Evidence form murine studies suggest that CCL25 and CCR9 are involved in lymphocyte recruitment to the small intestine but not the colon. We now show that although CCL25 is largely absent from non-inflamed human colon, expression is markedly upregulated in colitis and correlates with inflammatory activity. Moreover, CCL25 expression in the colon is associated with high frequencies of CCR9⁺ tissue-infiltrating effector T-cells in patients with colitis, which exhibit increased potential toward adhesion to liver endothelium. These findings are important for several reasons: firstly they support a role for CCL25 expression and CCR9⁺ effector cells in colitis and show that CCR9-dependent recruitment is not confined to regulatory cells; secondly they suggest that CCR9 is a potential therapeutic target in UC as well as colonic Crohn’s disease [8,27]; and thirdly they support a pathogenic role for effector T-cells activated in the colon, which have also been identified as being proinflammatory in PSC liver [12].

CCR9 is expressed on nearly all intraepithelial lymphocytes (IELs) and lamina propria lymphocytes (LPLs) in the jejunum, and at high frequencies in the terminal ileum [15]. In contrast, relatively few T-cells are reportedly CCR9 positive in the colon or mesenteric lymph nodes (MLN) [18]. Moreover, Papadakis et al. found low
frequencies of CD4+CCR9+ T-cells in the peripheral blood of patients with colonic as opposed to small bowel Crohn’s disease [28]. The same group reported low frequencies of CD3+CCR9+ cells in normal human colonic mucosa, consistent with our findings [18]. However, none of these studies looked in detail at inflamed human colon. We not only detected elevated frequencies of CCR9+ T-cells in active macroscopic colitis but also saw high (albeit relatively fewer) numbers in microscopic colitis. Taken together, our findings imply that activation of this pathway takes place early in colitis and is upregulated with disease activity [29].

Ccl25 gene expression is restricted to the small intestine in uninjured wild type mice [16,30,31] as well as the Samp1/YitFc model of IBD [32]. Similar results are reported in the TnfΔ40B model of small bowel Crohn’s disease [33], Rag2−/− mice [34] and studies in higher order mammals [35]. Nevertheless, certain studies do report colonic Ccl25 transcripts in spontaneous murine models of colitis [36], as well as colonic inflammation induced by dextran sulphate sodium [37,38] and oxazolone [39]. We extend upon these observations by showing a striking positive correlation between human colonic CCL25 gene expression and inflammatory indices across two patient cohorts with ulcerative colitis, in association with detectable CCL25 protein levels and a CCR9+ colon-infiltrating effector T-cell population. These findings may also contribute to the colonic cancer risk in IBD which relates to inflammatory burden, given the ability of CCR9/CCL25 interactions to mediate colonic tumour growth, invasion and metastasis [40].

The potential to imprint gut-tropism onto lymphocytes was long-believed as restricted to intestinal dendritic cells (DC) within the lamina propria and MLN [41], although works from the Blizzard institute (London, UK) have recently identified DC and CD14+ macrophages from the inflamed human colon as also possessing such capabilities [42]. Moreover, murine studies suggest that HSEC under certain circumstances can imprint gut-tropism through the generation of α4β7+CCR9+ T-cells. However, under such circumstances ‘HSEC-primed’ T-cells are dominated by regulatory functions, rather than ‘gut-primed’ α4β7+CCR9+ T-cells which exhibit an effector phenotype [43–45]. Our data builds upon these findings by showing how α4β7+CCR9+ T-cells undergo enhanced adhesion and transmigration across stimulated liver endothelium compared with their α4β7+CCR9− counterparts. In view of the evolving use of anti-CCR9 therapies in IBD, these findings support therapeutic exploration in models exhibiting concomitant features of cholangitis and colitis [45,46]; of particular relevance given that it is the CCR9 positive subset of mucosal T-cells which are implicated in the pathogenesis of PSC [12].

If CCL25 expression is driven by colitis activity, and colonic
CCR9⁺ T-cells are responsible for driving hepatobiliary inflammation in PSC, then it should follow that the risk of PSC increases with intestinal activity; an observation which does not hold true clinically. However, pre-exposure of primed CCR9⁺ T-cells to high CCL25 levels in the gut during the onset of active IBD, may be capable of modulating subsequent migratory responses [47]. In such a model, pro-inflammatory, effector mucosal CCR9⁺ T-cells would be preferentially recruited to the gut during the onset of active colonic disease in response to high levels of intestinal CCL25 expression. Thereafter, mucosal T-cells would down-regulate expression of active CCR9 ("chemokine desensitisation"), favouring local retention in the gut for as long as colonic inflammation persists. On achieving remission from a colitis flare, the colonic CCL25 gradient is attenuated, and primed mucosal CCR9⁺ lymphocytes now become permissive to recruitment to the liver sinusoids in response to aberrant hepatic endothelial CCL25 expression as observed in the PSC liver [12]. Of interest, the risk of PSC disease recurrence following liver transplantation appears greatest in patients with IBD who retain an intact colon [48–50]. However, the precise factors regulating endothelial expression of CCL25 in the native (and indeed transplanted) liver remain elusive, and command further investigation.

In summary, we report the involvement of CCL25 and CCR9 effector T-cells in colonic inflammation, providing further evidence to support a role for CCR9 in lymphocyte homing to the large bowel.

**Table 1**

Characteristics of patients undergoing colonoscopic surveillance (n = 37).

| Characteristic                          | Number of patients (%) |
|----------------------------------------|------------------------|
| Median age (IQR)                       | 38yrs. (26–46)         |
| Male; N (%)                            | 22 (59)                |
| Biopsy site; N (%)                     |                        |
| - rectum                               | 13 (35)                |
| - sigmoid                              | 16 (43)                |
| - descending colon                     | 3 (8)                  |
| - transverse colon                     | 1 (3)                  |
| - ascending colon                      | 2 (5)                  |
| - caecum                               | 2 (5)                  |
| Endoscopic Mayo score; N (%)           |                        |
| 0                                      | 11 (30)                |
| 1                                      | 11 (30)                |
| 2                                      | 10 (27)                |
| 3                                      | 5 (14)                 |
| Primary sclerosing cholangitis; N (%)  | 3 (8)                  |
| Aminosaliclytes                        |                        |
| - Oral                                 | 29 (78)                |
| - Topical                              | 2 (5)                  |
| Immunosuppression; N (%)               |                        |
| - Any                                  | 21 (57)                |
| - Corticosteroid (oral)                | 9                      |
| - Corticosteroid (topical)             | 3                      |
| - Anti-proliferative                    | 8                      |
| - Biologic                             | 10                     |
| - Calcineurin inhibitor                | 1                      |

*a* Includes those on combination therapy with >1 agent.

*b* Prednisolone was utilised in all cases.

*b* Budesonide or hydrocortisone.

*d* Azathioprine, 6-Mercaptopurine of Methotrexate.

*e* Infliximab or Adalimumab.

**Fig. 2.** Colonic CCL25 Expression under Non- and Pro-Inflammatory Conditions. CCL25 protein expression was determined by western blots post-immunoprecipitation, I.P. [A], probing for CCL25 in tissue lysates of resected terminal ileum/small bowel (SB), large bowel afflicted with ulcerative colitis (UC) and non-inflamed colon (NC). Band sizes in keeping with dimeric CCL25 are illustrated for samples probed following I.P. (+), the paired cleared lysate (–), and β-actin (housekeeping; cleared lysates only). Membranes bearing NC samples were subject to greater exposure times given the relatively low abundance/absence of CCL25 under non-inflammatory conditions and are therefore shown as a separate group. Differential expression of CCL25 in tissue samples was confirmed by ELISA [B]. Correlation with inflammatory burden was assessed in mucosal biopsy samples obtained during routine, surveillance colonoscopy (n = 37) by qRT-PCR. Given that CCL25 gene expression was not detectable in non-inflamed colon (control), data are presented relative to GUS-β (housekeeping gene) across endoscopic Mayo severity scores [C] and in correlation with TNFα expression [D]. Asterisks are indicative of statistically significant differences.
previously published data, support a role of CCR9/CCL25 interactions in driving recruitment of mucosal effector cells to the gut as well as liver in patients with ulcerative colitis.

Grant support and funding

PTJ, CW, SW, GMH and DHA all received funding from the NIHR BRU PJT is funded by a Wellcome Trust Clinical Fellowship Award (099907/Z/12/Z) TB and MM received funding from the Federal Ministry of Education and Research (BMBF) Germany (FKZ: 01 E0 1002). TB receives funding from the German Research Foundation (DFG) Germany (FKZ: BR4182/3-1).

Disclosures

This article presents independent research funded by the NIHR. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

Competing interests

None.

Appendix A. Supplementary data

Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.jaut.2016.01.001.

References

[1] M. Svensson, W.W. Agace, Role of CCL25/CCR9 in immune homeostasis and disease, Expert Rev. Clin. Immunol. 2 (2006) 795–773, http://dx.doi.org/10.1586/14746568.2.7.795.
[2] E.J. Kunkel, C.H. Kim, N.H. Lazarus, M.A. Vieria, D. Soler, E.P. Bowman et al., CCR10 expression is a common feature of circulating and mucosal epithelial tissue IgA Ab-secreting cells, J. Clin. Invest. 111 (2003) 1001–1010, http://dx.doi.org/10.1172/JCI17244.
[3] S.V. Kim, W.V. Xiang, C. Kwak, Y. Yang, X.W. Lin, M. Ota et al., GPRL5-mediated homing controls immune homeostasis in the large intestine mucosa, Science 340 (2013) 1456–1459, http://dx.doi.org/10.1126/science.1237013.
[4] L.P. Nguyen, J. Pan, T.T. Dinh, H. Hadeiba, E. O'Hara, A. Ebtikar et al., Role and tissue IgA Ab-secreting cells, J. Clin. Invest. 111 (2003) 1001–1010, http://dx.doi.org/10.1172/JCI17244.
[5] M. Apostolaki, M. Manoloukos, M. Roulis, M. Wurbel, W. Müller, K.A. Papadakis et al., Role of CCR9 in epithelial thymus-expressed chemokine receptor 9 in selective expression on intestinal homing T lymphocytes, mucosal lymphocytes, and thymocytes and is required for thymus-expressed chemokine–mediated chemotaxis, J. Exp. Med. 190 (1999) 1241–1256, http://dx.doi.org/10.1084/jem.190.9.1241.
[6] K.A. Papadakis, J. Prehn, V. Nelson, L. Cheng, S.W. Binder, P.D. Ponath et al., The role of thymus-expressed chemokine and its receptor CCR9 on lymphocytes in the regional specialization of the mucosal immune system, Immunol. 165 (2000) 5689–5697.
[7] D.H. Adams, B. Eksteen, Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease, Nat. Rev. Immunol. 6 (2006) 244–251, http://dx.doi.org/10.1038/nri1784.
[8] S.T. Ward, K.K. Li, E. Hepburn, C.J. Weston, S.M. Curbishley, G.M. Reynolds et al., The effects of CCR5 inhibition on regulatory T-cell recruitment to colorectal cancer, Br. J. Cancer 112 (2015) 319–328.
[9] P.F. Lalor, P.J. Sun, C.J. Weston, A. Martin-Santos, M.J.O. Wakelam, D.H. Adams, Activation of vascular adhesion protein-1 on liver endothelium results in an NF-kappaB-dependent increase in liver adhesion, Hepatology 45 (2007) 465–474, http://dx.doi.org/10.1002/hep.21497.
[10] F. Lukaus, M. Karikosi, G.M. Reynolds, P.F. Lalor, C.J. Weston, N. Pullen et al., Regulation of mucosal addressin cell adhesion molecule 1 expression in human and mice by vascular adhesion protein 1 amine oxidase activity, Hepatology 53 (2011) 661–672, http://dx.doi.org/10.1002/hep.24085.
[11] S.T. Ward, C.J. Weston, D.H. Adams, P.F. Lalor, A. Martin-Santos, D.F. Szabo et al., A flow analysis assay to study leukocyte recruitment to human hepatic sinusoidal endothelial under conditions of shear stress, J. Vis. Exp. JoVE (2014), http://dx.doi.org/10.3791/51310.
[12] P.K. Gage, T. Goeroge, J.E. Meyer, S. Maume, A comparative study of Chemokine rantes detection using ELISA and Western blot, Res. Commun. Mol. Pathol. Pharmacol. 110 (2001) 139–142.
[13] S. Danese, C. Fiochhi, Ulcerative colitis, N. Engl. J. Med. 365 (2011) 1713–1725, http://dx.doi.org/10.1056/NEJMra1012942.
[14] D.C. Baumgart, W.J. Sandborn, Crohn’s disease, Lancet 380 (2012) 1590–1605, http://dx.doi.org/10.1016/S0140-6736(12)60026-9.
[15] S. Keshav, T. Vanasse, Y. Niv, R. Petryka, S. Howaldt, M. Bafutto et al., A Randomized Controlled Trial of the Efficacy and Safety of CCX228-B, an orally-administered blocker of Chemokine receptor CCR5, for patients with Crohn’s disease, PLoS One 8 (2013) e56094.
[16] K.A. Papadakis, J. Prehn, S.T. Moreno, L. Cheng, E.A. Kouroulis, R. Deen et al., CCL29–Positive lymphocytes and thymus-expressed chemokine distinguish small bowel from colonic Crohn’s disease, Gastroenterology 121 (2001) 246–254, http://dx.doi.org/10.1053/gastro.2001.27154.
[17] F. Austichbach, B. Funke, M. Katzenmeyer, N. Gaisser, Expression of chemokine receptors in normal and inflamed human intestine, tonsil, and liver—a histochemical analysis with new monoclonal antibodies from the 8th international workshop and conference on human leukocyte differentiation antigens, Cell. Immunol. 236 (2005) 110–114, http://dx.doi.org/10.1016/j.cellimm.2005.08.016.
[18] H. Stenstad, M. Svensson, H. Cuak, K. Kotarsky, W.W. Agace, Differential homing mechanisms regulate regionalized effector CD19/CD25-b+ T cell accumulation within the normal gut immune system, Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 10122–10127, http://dx.doi.org/10.1073/pnas.0700269104.
[19] E. Ericsson, K. Kotarsky, M. Svensson, M. Sigvardsson, W. Agace, Functional characterization of the CCL25 Promoter in Small Intestinal Epithelial Cells Suggests a Regulatory Role for Caudal-Related Homeobox (Castlebox) Transcription Factors, J. Immunol. 176 (2006) 3642–3651, http://dx.doi.org/10.4049/jimmunol.176.6.3642.
[20] J. Rivera–Nieves, J. Ho, G. Bamas, N. Iwashkina, K. Ley, M. Oppermann et al., Antithymocyte Blockade of CCL25 downregulates the Late Thymus-expressed Chemokine CCL25 in murine ileitis, Gastroenterology 131 (2006) 1518–1529, http://dx.doi.org/10.1053/j.gastro.2006.08.031.
[21] D.W. Wermers, E.W. MacNamee, M.A. Wurbel, P. Judicka, J. Rivera–Nieves, The chemokine receptor CCR9 is required for the T-cell-mediated regulation of chronic ileitis in mice, Gastroenterology 141 (2011), http://dx.doi.org/10.1053/j.gastro.2011.01.045, 1526–1535.e3.
[22] S. Mizuno, T. Kani, Y. Mikami, T. Sujoji, Y. Ono, A. Hayashi et al., CCR9–plasmacytoid dendritic cells in the small intestine suppress development of P.J. Trivedi et al. / Journal of Autoimmunity xxx (2016) 1–7

Please cite this article in press as: P.J. Trivedi et al., Intestinal CCL25 expression is increased in colitis and correlates with inflammatory activity, Journal of Autoimmunity (2016), http://dx.doi.org/10.1016/j.jaut.2016.01.001.
intestinal inflammation in mice, Immunol. Lett. 146 (2012) 64–69, http://dx.doi.org/10.1016/j.imlet.2012.05.001.

[35] F. Meurers, M. Berri, R.H. Siggers, B.P. Willing, H. Salmon, A.G. Van Kessel, et al., Commensal bacteria and expression of two major intestinal chemokines, TECK/CCL25 and MEC/CCL28, and their receptors, PloS One 2 (2007) e677, http://dx.doi.org/10.1371/journal.pone.0000677.

[36] P. Bekker, K. Ebsworth, M.J. Walters, R.D. Berahovich, L.S. Ertl, T.T. Charvat, et al., CCR9 Antagonists in the Treatment of Ulcerative Colitis, CCR9 Antagonists in the Treatment of Ulcerative Colitis, Mediat. Inflamm. Mediat. Inflamm. 2015 (2015) e628340, http://dx.doi.org/10.1155/2015/628340.

[37] M.-A. Wurbel, M.G. McIntire, P. Dwyer, E. Fiebiger, CCL25/CCR9 interactions are not essential for colitis development but are required for innate immune cell protection from chronic experimental murine colitis, Inflamm. Bowel Dis. 20 (2014) 1165–1176, http://dx.doi.org/10.1097/MBI.0000000000000559.

[38] S. Zhu, Y. Bing, X. Wang, Q. Yu, Y. Wang, S. Xu, et al., CCL25/CCR9 interactions regulate the function of iNKT cells in oxazolone-induced colitis in mice, PloS One 9 (2014) e100167, http://dx.doi.org/10.1371/journal.pone.0100167.

[39] H.J. Chen, R. Edwards, S. Tucci, P. Bu, J. Milsom, S. Lee, et al., Chemokine 25-induced signaling suppresses colon cancer invasion and metastasis, J. Clin. Invest. 122 (2012) 3184–3196, http://dx.doi.org/10.1172/JCI62110.

[40] B. Eksteen, J.R. Mora, E.L. Haughton, N.C. Henderson, L. Lee-Turner, E.J. Villablanca, et al., Gut homing receptors on CD8 T cells are retinoic acid dependent and not maintained by liver dendritic or stellate cells, Gastroenterology 137 (2009) 320–329, http://dx.doi.org/10.1053/j.gastro.2009.02.046.

[41] T.J. Sanders, N.E. McCarthy, E.M. Giles, K.L.M. Davidson, M.L.R. Haltalli, S. Hazell, et al., Increased production of retinoic acid by intestinal macrophages contributes to their inflammatory phenotype in patients with Crohn’s disease, Gastroenterology 146 (2014), http://dx.doi.org/10.1053/j.gastro.2014.01.057, 1278–1288.e2.

[42] K. Neumann, N. Kruse, B. Szilagyi, U. Erben, C. Rudolph, A. Flach, et al., Connecting liver and gut: murine liver sinusoidal endothelium induces gut tropism of CD4+ T cells via retinoic acid, Hepatology 55 (2012) 1976–1984, http://dx.doi.org/10.1002/hep.24816.

[43] N. Kruse, K. Neumann, A. Schrage, K. Derkow, E. Schott, U. Erben, et al., Priming of CD4+ T cells by liver sinusoidal endothelial cells induces CD25low forhead box protein 3-regulatory T cells suppressing autoimmune hepatitis, Hepatology 50 (2009) 1904–1913, http://dx.doi.org/10.1002/hep.23151.

[44] I. Eickmeier, D. Seidel, J.R. Grün, K. Derkow, S. Lehnardt, A.A. Kühl, et al., Influence of CCR9 T cell priming in liver and gut on the enterohepatic circulation, J. Hepatol. 60 (2014) 1143–1150, http://dx.doi.org/10.1016/j.jhep.2014.02.011.

[45] D. Seidel, I. Eickmeier, A.A. Kühl, A. Hamann, C. Loddenkemper, E. Schott, CCR9 T cells primed in the gut-associated lymphoid tissue induce immune-mediated cholangitis in mice, Hepatology 59 (2014) 601–611, http://dx.doi.org/10.1002/hep.26702.

[46] N. Hosoe, S. Miura, C. Watanuki, Y. Tsuzuki, R. Hokari, T. Oyama, et al., Demonstration of functional role of TECK/CCL25 in T lymphocyte-endothelium interaction in inflamed and uninflamed intestinal mucosa, Am. J. Physiol. Gastrointest. Liver Physiol. 286 (2004) G458–G466, http://dx.doi.org/10.1152/ajpgi.00167.2003.

[47] E. Alabrabia, P. Nightingale, B. Gunson, S. Hubischer, S. Olliff, D. Mirza, et al., A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis after liver transplantation, Liver Transpl. 15 (2009) 330–340, http://dx.doi.org/10.1002/hep.21679.

[48] N. Hildebrand, N. Pannicke, A. Dechene, D.N. Gotthardt, G. Kirchner, F.P. Reiter, et al., Biliary strictures and recurrence after liver transplantation for primary sclerosing cholangitis: A retrospective multicenter analysis: biliary strictures and PSC recurrence, Liver Transpl. 22 (2016) 42–52, http://dx.doi.org/10.1002/hep.24350.

[49] R. Ravikumar, E. Tsochatzis, S. Jose, M. Allison, A. Athale, F. Creamer, et al., Risk factors for recurrent primary sclerosing cholangitis after liver transplantation, J. Hepatol. 63 (2015) 1139–1146, http://dx.doi.org/10.1016/j.jhep.2015.07.005.